Interferon Alfa‐2b or Not 2b? Significant Differences Exist in the Decision‐Making Process between Melanoma Patients Who Accept or Decline High‐Dose Adjuvant Interferon Alfa‐2b Treatment
Overview of attention for article published in Dermatologic Surgery, January 2007
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (74th percentile)
-
Good Attention Score compared to outputs of the same age and source (65th percentile)
Readers on
- mendeley
- 52 Mendeley